IDH1 and cancer: In this case, the large decrease in the binding affinity of R132H for Mg2+ allows nanomolar concentrations of ivosidenib to selectively inhibit the cancer-associated variants—a conclusion that could only be directly confirmed by testing ivosidenib against a mixed population of active variant/wildtype IDH1 enzymes.